Oraticx Achieves Patent for Respiratory Disease Prevention and Treatment
Ready to unleash the power of probiotics?
Revolutionize your oral care routine with OraTicx probiotics!
Oraticx Achieves Patent for Respiratory Disease Prevention and Treatment
Breakthrough in Respiratory Disease Treatment
Oraticx, a company specializing in oral probiotics, proudly announced the completion of a patent registration for a "composition for the prevention and treatment of respiratory diseases." This marks their 10th patent milestone, following the publication of a preclinical study in the SCIE-grade international journal 'Medicina' on the effectiveness of improving allergic inflammation caused by automobile fine dust (DEPM).
Revolutionizing Respiratory Care
With this new patent, Oraticx aims to bring significant advancements to respiratory care, which currently relies heavily on mask-wearing and routine management. While many believe respiratory health only requires attention during the cold winter months, summer is also a critical period. Fine dust persists throughout the year, and air conditioner use in summer often leads to colds.
The Threat of Fine Dust
Fine dust is notorious for worsening respiratory diseases. It adheres to the lungs and airways, causing cellular-level DNA damage and potentially leading to cancer. The International Agency for Research on Cancer (IARC), under the World Health Organization (WHO), classifies fine dust as a Group 1 carcinogen.
25+ Years of Research and Innovation
OraTicx has over 25 years of experience in research, with more than 36 published studies on our unique bacterial strains.
Oraticx: Pioneering Oral Care Innovations
Since obtaining their first patent in 2006 for a probiotic that suppresses bad breath, Oraticx has been at the forefront of oral care innovation. Their portfolio includes patents for compositions that prevent or improve dental caries, periodontal disease, and peri-implant mucositis. More recently, they have secured patents for compositions targeting upper respiratory tract infections, acute respiratory virus infections, and rotavirus infections, linking oral health closely with upper respiratory health.
Details of the New Patent
The newly acquired patent introduces a composition for the prevention and treatment of respiratory diseases, featuring Oraticx’s proprietary oraCMU or oraCMS1 probiotics as active ingredients. The respiratory diseases covered include bronchitis, tuberculosis, pneumonia, pneumoconiosis, asthma, colds, influenza, allergic rhinitis, sinusitis, upper and lower respiratory tract infections, pharyngitis, tonsillitis, laryngitis, and emphysema. Notably, asthma can be bronchial or allergic and may be triggered by fine dust, house dust, mites, pollen, or mold.
Commitment to Research and Innovation
With this new patent, Oraticx now holds 10 patents in Korea and the United States, has completed 10 human application trials, and published 36 research papers. Their oral probiotic strains oraCMU® and oraCMS1®, developed by the Oraticx research institute, were chosen as the most effective among 1,640 strains derived from the mouths of 460 Korean children. The "effect of oraCMU® on improving bad breath" study, conducted jointly with the Seoul National University Dental Hospital research team, was published in the SCIE-grade international journal 'Frontiers in Microbiology.' Furthermore, the safety and quality of these ingredients were validated through registration with the US FDA GRAS.
Oraticx continues to lead the way in both oral and respiratory health innovations, ensuring a healthier future for all.
